Novo Nordisk A/S (NYSE:NVO) initiated legal action against Eli Lilly and Co (NYSE:LLY) and Lilly USA, LLC, alleging deceptive marketing practices.
The lawsuit, filed in the U.S.
District Court for the District of New Jersey, accuses the competitor of violating both state and federal false advertising and unfair competition laws.
The core of the dispute centers on nationwide consumer campaigns for Zepbound and Mounjaro.
The plaintiff claims that the advertisements are materially misleading to millions of patients managing obesity and type 2 diabetes.
